Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. It is an oral, selective ACTH antagonist.
Atumelnant is now in Phase 2 of development and you can read the latest research results at the link below:
Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results From a12-Week, Phase 2, Open-Label Study
Richard J. Auchus, MD, PhD, Peter J. Trainer, MD, Kathryn Jean Lucas, MD3, et al
Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024
Click here to read more about Alumelnant on Crinetics’ website.
Recent Blog Posts
Webinar: Quality of life and fertility in CAH – 21st November 2026
The European Society for Endocrinology (ESE) is running a free webinar focussing on CAH on 21st November 2026. Hear from patients and clinicians from across Europe as the subjects of health-related quality of life and preserving fertility across the lifespan are...
Supporting Safer Adrenal Crisis Care
The Addison’s Disease Self-Help Group (ADSHG) has launched a national advocacy campaign to improve emergency treatment and patient safety for people at risk of adrenal crisis. The campaign was sparked by the discontinuation of liquid hydrocortisone in the UK, which...
Pituitary Awareness Month (October) – Symptoms in the Spotlight
October is Pituitary Awareness Month. Although not CAH, some of the information from the Pituitary Foundation may be helpful for those living with CAH. Find out more at the Pituitary Foundation's website here. Header image from Pituitary Foundation UK. Recent Blog...